Cytokinetics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
77,728.00
83,228.00
111,442.00
156,249.00
268,891.00
198,731
Total Accounts Receivable
220.00
46,755.00
243.00
224.00
1,112.00
6,785
Other Current Assets
1,390.00
1,148.00
1,422.00
2,160.00
4,292.00
2,158
Total Current Assets
79,338.00
131,131.00
113,107.00
158,633.00
274,295.00
207,674
Net Property, Plant & Equipment
1,221.00
1,637.00
1,751.00
3,637.00
3,568.00
3,204
Total Investments and Advances
2,502.00
-
179.00
7,672.00
16,518.00
-
Other Assets
127.00
200.00
200.00
200.00
429.00
300
Total Assets
83,188.00
132,968.00
115,237.00
170,142.00
294,810.00
211,178
ST Debt & Current Portion LT Debt
-
-
-
2,500.00
-
Accounts Payable
3,709.00
1,361.00
2,238.00
4,236.00
5,253.00
Other Current Liabilities
22,995.00
22,494.00
29,411.00
26,522.00
27,191.00
Total Current Liabilities
26,704.00
23,855.00
31,649.00
33,258.00
32,444.00
Long-Term Debt
-
-
14,639.00
27,381.00
31,777.00
Other Liabilities
2,042.00
17,049.00
359.00
15,142.00
120,747.00
Total Liabilities
28,746.00
40,904.00
46,647.00
75,781.00
184,968.00
Common Equity (Total)
54,442.00
92,064.00
68,590.00
94,361.00
109,842.00
Total Shareholders' Equity
54,442.00
92,064.00
68,590.00
94,361.00
109,842.00
Total Equity
54,442.00
92,064.00
68,590.00
94,361.00
109,842.00
Liabilities & Shareholders' Equity
83,188.00
132,968.00
115,237.00
170,142.00
294,810.00

About Cytokinetics

View Profile
Address
280 East Grand Avenue
South San Francisco California 94080
United States
Employees -
Website http://www.cytokinetics.com
Updated 07/08/2019
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.